Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
5.23
+0.01 (0.19%)
At close: Nov 20, 2024, 4:00 PM
5.31
+0.08 (1.53%)
Pre-market: Nov 21, 2024, 4:04 AM EST
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for AMLX stock have an average target of 7.60, with a low estimate of 3.00 and a high estimate of 12. The average target predicts an increase of 45.32% from the current stock price of 5.23.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AMLX stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Hold → Buy Upgrades $3 → $11 | Hold → Buy | Upgrades | $3 → $11 | +110.33% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +129.45% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +52.96% | Oct 18, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | -23.52% | Jul 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +52.96% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
89.36M
from 380.79M
Decreased by -76.53%
Revenue Next Year
222.95M
from 89.36M
Increased by 149.49%
EPS This Year
-4.32
from 0.70
EPS Next Year
-1.92
from -4.32
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 92.0M | 601.3M | 677.3M | ||
| Avg | 89.4M | 223.0M | 259.8M | ||
| Low | 85.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -75.8% | 572.9% | 203.8% | ||
| Avg | -76.5% | 149.5% | 16.5% | ||
| Low | -77.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.98 | -1.47 | -0.76 | ||
| Avg | -4.32 | -1.92 | -1.68 | ||
| Low | -4.61 | -2.84 | -3.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.